Gruppo FarmaImpresa completes the registration process for an oral emulsion for Gastroesophageal Reflux Disease Treatment
With pride, we present our recent success in obtaining registration for a Class IIa medical device in Vietnam. This device, based on low molecular weight hyaluronic acid, sodium alginate, myrrh extract, and simethicone, is indicated for the treatment of gastroesophageal reflux disease (GERD).
Our product, an oral emulsion, provides relief for a wide range of disorders associated with reflux, including Non-Erosive Reflux Disease (NERD), functional heartburn, and esophageal sensitivity to acid reflux. This is made possible by its viscous formulation, which allows the product to adhere to and coat the esophageal mucosa, creating an effective protective barrier.
Hyaluronic acid, a naturally occurring component in our bodies, plays a crucial role in providing hydration and protection to the mucous membranes of the gastroesophageal tract. Additionally, it promotes the repair process of damaged epithelium, promoting faster and more complete healing.
Simethicone, with its physicochemical properties, plays a fundamental role in reducing the surface tension of gases present in gastric fluid. This facilitates the elimination of gases, moderating the pressure they exert on gastric fluid and helping to prevent reflux.
Sodium alginate, another key ingredient in our formulation, creates a viscous barrier that prevents the rise of gastric contents into the esophagus. This mechanism of action provides an additional level of protection and helps control symptoms associated with gastroesophageal reflux.
Stay tuned for updates on our upcoming certifications worldwide.
